At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
View Top Employees from Mersana TherapeuticsWebsite | http://www.mersana.com |
Ticker | MRSN |
Revenue | $10 million |
Funding | $366.3 million |
Employees | 253 (253 on RocketReach) |
Founded | 2001 |
Address | 840 Memorial Drive, Cambridge, Massachusetts 02139, US |
Phone | (617) 498-0020 |
Technologies |
JavaScript,
HTML,
PHP
+46 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Healthcare, Science and Engineering, Medical, Health Care, Therapeutics |
Web Rank | 4 Million |
Keywords | Cancer Treatment, Precision Oncology, Targeted Cancer Therapies |
Competitors | Allakos Inc, Ambrx, Biokine Therapeutics Ltd., Leap Therapeutics, Mirati Therapeutics Inc |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Mersana Therapeutics employee's phone or email?
The Mersana Therapeutics annual revenue was $10 million in 2024.
Brian DeSchuytner is the CFO of Mersana Therapeutics.
253 people are employed at Mersana Therapeutics.
Mersana Therapeutics is based in Cambridge, Massachusetts.
The NAICS codes for Mersana Therapeutics are [32541, 3254, 32, 325].
The SIC codes for Mersana Therapeutics are [283, 28].